BioSpace News Archive

Telegraph Hill Partners (THP), a leading venture capital and growth equity firm dedicated exclusively to life science and healthcare investing, today announced the addition of Raymond Falci to its investment team.

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, November 14, 2022, at 4:30 p.m. Eastern Time to review 2022 third quarter results.

Shoreline Biosciences, Inc. today announced the appointment of Charles Calderaro III as Chief Technical Officer.

Sebela Pharmaceuticals, a US pharmaceutical company with a market leading position in gastroenterology and a focus on innovation in women’s health, today announced the appointment of Victor Parker to the position of Chief Commercial Officer.

Health Union, the leader in social health, has been accepted to present research about irritable bowel syndrome symptom control, relationships with healthcare professionals and perceived quality of care at the 2022 Annual Scientific Meeting of the American College of Gastroenterology, also known as ACG 2022.

MDimune, Inc., a Korean biotech company developing BioDroneTM platform technology based on cell-derived vesicles (CDVs), enters into an MOU with SensoryCure to collaborate on the development of therapeutics for hearing loss.

University of Michigan research team is first to perform virtual clinical trials using a multi-scale lung model, with early results expected next year

On 09 September 2022, Australia welcomed its first bioanalytical laboratory inside a Phase 1 clinical unit.

BioSig Technologies, Inc. announced that it will sponsor a research agreement with Cleveland Clinic Foundation to investigate expanded clinical applications for the intracardiac signals acquired by its PURE EP™ System.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx” or “Company”) is reporting today that its U.S. joint venture (JV) partner and licensee, HLB Therapeutics (HLBT), has announced that it submitted a request for the Special Protocol Assessment (SPA) to the U.S. FDA for an in-depth discussion and assessment of the clinical protocol for a fourth phase 3 clinical trial (ARISE-4) for the treatment of dry eye disease.